How I Treat: MRD testing to personalize allogeneic HCT for adults with AML

The authors explore how measurable residual disease (MRD) testing can be utilized to personalize allogeneic hematopoietic cell transplantation (allo-HCT) for adults with acute myeloid leukemia (AML). They aim to address the potential of MRD testing in improving patient selection, conditioning regimens, and post-transplant surveillance, while acknowledging the current limitations and uncertainties surrounding its interpretation and application in clinical practice. Through four case studies, the authors illustrate the practical use of MRD testing in managing AML patients undergoing allo-HCT.